Neurokine

Neurokine Pharmaceuticals was a clinical-stage biotechnology company focused on developing novel therapies for neuroinflammatory conditions, specifically targeting Alzheimer's disease. The company's lead candidate, NK-001, was a proprietary formulation of diclofenac designed to cross the blood-brain barrier more effectively to reduce brain inflammation. Neurokine aimed to repurpose and optimize existing small molecules to address the high unmet need in neurodegenerative disorders. The company was eventually acquired by IntelGenx, which sought to integrate Neurokine's neuro-focused assets with its own drug delivery technologies.